萬(wàn)密密副教授課題組在ACS APPLIED MATERIALS & INTERFACES發(fā)表研究論文
Erythrocyte Membrane-Wrapped Magnetic Nanotherapeutic Agents for Reduction and Removal of Blood Cr(VI)
Wang, M (Wang, Meng)[ 1 ] ; Yan, WQ (Yan, Wenqiang)[ 2 ] ; Chu, ML (Chu, Meilin)[ 1 ] ; Li, T (Li, Ting)[ 1 ] ; Liu, ZY (Liu, Zhiyong)[ 1 ] ; Yu, YQ (Yu, Yueqi)[ 1 ] ; Huang, YY (Huang, Yangyang)[ 1 ] ; Zhu, TY (Zhu, Tianyu)[ 1 ] ; Wan, MM (Wan, Mimi)[ 1 ]*（萬(wàn)密密）; Mao, C (Mao, Chun)[ 1 ] ; Shi, DQ (Shi, Dongquan)[ 2 ]*
[ 1 ] Nanjing Normal Univ, Natl & Local Joint Engn Res Ctr Biomed Funct Mat, Sch Chem & Mat Sci, Nanjing 210023, Peoples R China
[ 2 ] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Sports Med & Adult Reconstruct Surg, Nanjing 210008, Peoples R China
ACS APPLIED MATERIALS & INTERFACES，202006,12(25),28014-28023
The hazard of hexavalent chromium (Cr(VI)) from environmental pollution and medical implanted metal has been recognized widely. However, removal of trace amount of Cr(VI) in the blood circumstance faces tremendous difficulties for that most of Cr(VI) located in erythrocytes, thus there is almost no literature to report the removal of Cr(VI) in blood. Herein, a removal strategy, named as reduction-adsorption-separation, is proposed to realize the removal of Cr(VI) in blood. First, magnetic core-shell mesoporous nanocomposite is fabricated by using Fe3O4 nanoparticles as magnetic core and mesoporous silica (MS) as shell, hyperbranched polyamide (HPA) as mesoporous channel modifier and ascorbic acid (ASC) as the reductant drug loaded in the mesoporous channels, which is also denoted as Fe/MS/HPA/ASC. Then, on the basis of the bionic idea, the erythrocyte membrane (EM)-wrapped Fe/MS/HPA/ASC to protect ASC from deactivation is obtained and named as the therapeutic agent (Fe/MS/HPA/ASC@EM). During removal process, the therapeutic agent can enter in erythrocytes to use ASC to reduce Cr(VI) to Cr(III) and HPA in mesoporous channels to adsorb Cr(III) and can then be recollected from blood by magnetic separation. Finally, an animal model of blood Cr(VI) poisoning is constructed and used to test the removal ability of Cr(VI) from pig blood in vivo, verifying the effectiveness of this blood Cr(VI) removal strategy, providing a possible way to design more efficient and biosafe therapeutic agents for blood purification.
文章鏈接：
https://pubs.acs.org/doi/10.1021/acsami.0c06437
版權(quán)與免責(zé)聲明：本網(wǎng)頁(yè)的內(nèi)容由收集互聯(lián)網(wǎng)上公開(kāi)發(fā)布的信息整理獲得。目的在于傳遞信息及分享，并不意味著贊同其觀點(diǎn)或證實(shí)其真實(shí)性，也不構(gòu)成其他建議。僅提供交流平臺(tái)，不為其版權(quán)負(fù)責(zé)。如涉及侵權(quán)，請(qǐng)聯(lián)系我們及時(shí)修改或刪除。郵箱：sales@allpeptide.com